Study:
Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine Plus Hematopoietic Stem Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia
Rationale:
Giving chemotherapy drugs, such as R115777, isotretinoin, cytarabine, and
fludarabine, before a donor bone marrow transplant or an umbilical cord transplant helps
stop the growth of cancer cells. It also helps stop the patient`s immune system from
rejecting the donor`s stem cells. When the healthy stem cells from a donor are infused into
the patient they may help the patient`s bone marrow make stem cells, red blood cells, white
blood cells, and platelets.
Purpose:
This phase II trial is studying how well giving combination chemotherapy together
with donor bone marrow or umbilical cord blood transplant works in treating children with
newly diagnosed juvenile myelomonocytic leukemia.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Leukemia |
Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: cytarabine
Drug: fludarabine phosphate
Drug: isotretinoin
Drug: tipifarnib
Procedure: allogeneic bone marrow transplantation
Procedure: umbilical cord blood transplantation
Radiation: radiation therapy |
Phase 2 |
Verified by
Children`s Oncology Group
November, 2010
Sponsored by: Children`s Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00025038
Study Type: Interventional
Study Design: Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195-5217
United States
Robert P. Castleberry, MD., Study Chair